These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11674883)

  • 1. Clinical inquiries. What are the indications for treatment with angiotensin-converting enzyme (ACE) inhibitors in patients with diabetes?
    Loomis LW; Quint A
    J Fam Pract; 2001 Oct; 50(10):842-3. PubMed ID: 11674883
    [No Abstract]   [Full Text] [Related]  

  • 2. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL; Craddock D; Edwards K
    Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical inquiries. Are there big differences among beta-blockers in treating essential hypertension?
    Sontheimer D; Hitchcock K; Saseen J
    J Fam Pract; 2007 Apr; 56(4):312-4. PubMed ID: 17403332
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of hypertension in patients with chronic kidney disease and diabetes mellitus.
    Palmer BF
    Am J Med; 2008 Aug; 121(8 Suppl):S16-22. PubMed ID: 18638614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
    Pierson CA; Epstein BJ; Roberts ME
    J Am Acad Nurse Pract; 2008 Nov; 20(11):529-38. PubMed ID: 19128336
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ; Gums JG
    Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Type 2 diabetes. Routine ACE inhibitors?].
    Hönl SB
    Med Monatsschr Pharm; 2008 Apr; 31(4):149-50. PubMed ID: 18497249
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hypertension 2007-2008].
    Chatzikyrkou C; Menne J; Haller H
    Med Klin (Munich); 2009 Aug; 104(8):614-21. PubMed ID: 19701732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
    Abuissa H; Jones PG; Marso SP; O'Keefe JH
    J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
    Asselbergs FW; van Gilst WH
    Curr Opin Cardiol; 2007 Jul; 22(4):267-72. PubMed ID: 17556876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiotensin converting enzyme inhibitors in arterial hypertension and cardiac failure. The question of the dose].
    González-Juanatey JR
    Med Clin (Barc); 2000; 114 Suppl 2():24-7. PubMed ID: 10916802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experiences with the realisation of innovative study designs using the example of the HOPE-study].
    Rangoonwala B
    Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S82-5. PubMed ID: 15988674
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of hypertension in the elderly].
    Hohage H; Gerhardt U; Suwelack BM
    Med Klin (Munich); 2003 Sep; 98(9):511-21. PubMed ID: 14551708
    [No Abstract]   [Full Text] [Related]  

  • 19. [Coronary artery disease in patients with diabetes mellitus and its treatment].
    Teramoto T
    Nihon Naika Gakkai Zasshi; 2002 Mar; 91 Suppl():94-9. PubMed ID: 11989270
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.